Dr. Falk Pharma GmbH
http://www.falkfoundation.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Dr. Falk Pharma GmbH
Oncology Reinvents Itself To Retain Position As Biotech Investors’ Darling
Experts from across the biotech ecosystem spoke at a Citeline-sponsored panel at Swiss Biotech Day to discuss how pent-up demand was driving investment in areas outside of oncology, but how there was still room for innovation within the cancer market for those who ask the right questions.
Newron’s Add-On Treatment Shows Promise In Newly Popular Schizophrenia Field
Newron’s evenamide worked in a Phase II/III trial as an add-on to antipsychotic drugs in patients with inadequate response to monotherapy at a time when schizophrenia has piqued the interest of big pharma.
BMS Will Cut $1.5bn And 2,200 Jobs To Reinvest In Needed Growth
Revlimid and Eliquis beat expectations in the first quarter, but the products have dwindling exclusivity, making new drugs the main focus for Bristol. So the company will reinvest cost savings in R&D.
PureTech Hopes For A Second Lightning Strike
Emerging Company Profile: Seaport Therapeutics believes its technology can alter old drugs to remove their flaws. Just how closely can it follow the example set by Karuna?
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice